Anti-TCRβ mAb in Combination With Neurogenin3 Gene Therapy Reverses Established Overt Type 1 Diabetes in Female NOD Mice-Reference-Cited by-同舟云学术

Anti-TCRβ mAb in Combination With Neurogenin3 Gene Therapy Reverses Established Overt Type 1 Diabetes in Female NOD Mice

Published:2017-08-03 Issue:10 Volume:158 Page:3140-3151
ISSN:0013-7227
Container-title:Endocrinology
language:en
Short-container-title:

Author:

Xie Aini¹²³,Li Rongying²,Jiang Tao¹,Yan Hui¹,Zhang Hedong¹,Yang Yisheng²,Yang Lina²,Yechoor Vijay²,Chan Lawrence²,Chen Wenhao¹²⁴

Affiliation:

1. Center for Immunobiology and Transplantation Research, Department of Surgery, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas 77030

2. Division of Diabetes, Endocrinology & Metabolism, Diabetes & Endocrinology Research Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030

3. Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

4. Department of Surgery, Weill Cornell Medical College of Cornell University, New York, New York 10065

Publisher

The Endocrine Society

Subject

Endocrinology

Link

http://academic.oup.com/endo/article-pdf/158/10/3140/20424620/en.2016-1947.pdf

Reference25 articles.

1. Mechanistic basis of immunotherapies for type 1 diabetes mellitus;Chen;Transl Res,2013

2. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial;Näntö-Salonen;Lancet,2008

3. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus;Ludvigsson;N Engl J Med,2012

4. Immunotherapy of type 1 diabetes: where are we and where should we be going?;Luo;Immunity,2010